12 odpowiedzi w tym temacie

[mentin]

Witam wszystkich. Czy moge was prosic o rozpiske z nastepujacych srodków ( Rozpiska nie jest dla mnie tylko dla kumpla w celu sprawdzenia jego wiedzy bo on juz troche koksuje i chce zobaczyc jak wy mu to zaproponujecie ) Nie bede wam pisał jakie miał wczesniej kuracje
bo troche ich było .......Anapolon 60 tabsów (z tego chce zrobic front) 2 tabsy dziennie (Oczywiscie Sylimarol na a hepatil po cyklu dieta tez bedzie odpowiednia oraz suple )
Po skonczeniu Anapolonu chce walic Dece 2ml/tydz. (Ma 12 amp.) Omke 1 amp. co 3 dni (Tescia chce pociagnac 2 tygodnie dłuzej) I porosze was o odblok do tego.....

[Greater]

niech se daruje ten anapolon zamiast niego da mete i bedzie gitarra

[vadz]

Debilny cykl. Dece trzeba brac odrazu, Anapolon zaczynaj od 1 tab/dz., 2 taby moze okazac sie troche za mocne. 2 ml/tydz deki to smieszne dla kogos kto juz siega po anapolon, 4 ml/tydz minimum. Do tego od razy zaczynamy jakis testosteron, najlepiej enantat - 500 mg/tydz. Po 8 tydz. zaczynaj Winstrol i wymien testosteron enantat na propionat, to pomoze utrzymac mase osiagniete na Anapolonie i enantacie, po skonczeniu cyklu.
Wygladac to musi nastepujaco:
Tydz.Anapolon Testosteron enantat Deca Durabolin Winstrol Testosteron Propionat
1 50 500 400 0 0
2 100 500 400 0 0
3 100 500 400 0 0
4 100 500 400 0 0
5 0 500 400 0 0
6 0 500 400 0 0
7 0 500 400 0 0
8 0 0 0 50/ED 50/EOD
9 0 0 0 50/ED 50/EOD
10 0 0 0 50/ED 50/EOD
11 CLOMID 100 mg/ED
12 CLOMID 50 mg/ED
13 CLOMID 50 mg/ED
14 CLOMID 50 mg/ED

Na cyklu moze byc potrzebny Nolvadex - 20 mg/ED.


Sylimarol NIGDY nie brac na cyklu!! Poza tym ze nie da cie zadnych korzystnych efektow, ale jeszcze i zmniejszy efektywnosc doustnych sterydow, wspomagajac watrobe szybciej je wyeliminowac.

[Greater]

vadz a widziales z jakich srodkow on chcial rozpisake?? bo chyba propa i winka nie bylo tam


i pisze jeszcze raz. daruj sobie ten anapolon.
po co ci to??
deka + oma + meta i masz extra cykl.
1-12 deka 200me e7d
1-13 omo 250mg e3d
1-4 i 10-13 meta 25mg ed
2 tygodnie po cyklu ropoczynasz odblok

[Kafar1418048738]

fajny cykl chce kolega zapodac z anapolonu niech zrezygnuje ja bym polecal:
1-11 enantat 400mg
1-10 300mg deca
1-4(5) 25mg meta

[Shrek1418048757]

panowie co wy na to 120 anapolonu 25 sustenonu 30deki 2 butelki test jeka czy to dobry cykl???rozpiszcie jak to brac mysle ze to jest kozak

[ Dodano: 2005-10-09, 20:01 ]
panowie co jest jaki jest dobry koks na rynku

[crusher1988]

a Ty Shrek z choinki sie urwales czy co ??

[kujsus]

panowie co wy na to 120 anapolonu 25 sustenonu 30deki 2 butelki test jeka czy to dobry cykl???rozpiszcie jak to brac mysle ze to jest kozak

śmierć na miejscu...
mentin, omka za często, teść nie potrzebny, deki za dużo, natomiast zamiast Anapolonu mógłby wziąść metke...

[vadz]

Heh, no to jest wymagane, zeby zatrzymac to co cie daje Anapolon. Niestety pozostale skladniki tez sa wymagane.

Ciekawe ile wazy ten twoj koles w ogole? Jak nizej 100 kg to naprawde meta mu wystarczy. Zostaw anapolon dla tych kto go bardziej potrzebuje.

P.S. Ciekawostka- wlasnie niedawno temu zakupilem sobie 400 tab tureckiego Anapolonu, bede wkrotce probowac, powiem wam jak poszlo .

[dawid1920]

Sylimarol NIGDY nie brac na cyklu!! Poza tym ze nie da cie zadnych korzystnych efektow, ale jeszcze i zmniejszy efektywnosc doustnych sterydow, wspomagajac watrobe szybciej je wyeliminowac.

Możesz napisac cos więcej o tym? Skąd masz takie informacje?

[vadz]

Wlasnie dla tego ze nie bylo zrobiono zadnych badan klinicznych, okreslajacych efektywnosc Sylimarolu w stanach niezdolnosci watroby. Jedyny sprawdzony srodek, ktory dziala to Essentiale Forte podawany DOZYLNIE. Poza tym, toksycznosc doustnych sterydow jest mocno przesadzona. Dla ciekawostki - kliniczne dawki oksimetolonu (anapolon), w ciezkich stanach anemii, moga osiagnac nawet 10 mg/kg wagi co znaczy ktos kto ma wage 70 kg, musial by przyjmowac 700 mg (!!!) anapolonu przez okres czesto trwajacy miesiace. Nie istnieje zadnych klinicznie potwierdzonych przypadkow raka watroby, spowodowanych przez metandienon albo oksimetolon.

[kujsus]

Nie istnieje zadnych klinicznie potwierdzonych przypadkow raka watroby, spowodowanych przez metandienon albo oksimetolon.

ta... a bóle wątroby podczas cyklu się zdażają... i co na to odpowiesz??
Pozatym weź dużo mety i na bank wystapi żółtaczka... i co może to też nie jest potwierdzone klinicznie??

[vadz]

Zoltaczka i bole watroby to efekty odwracalne, i znikaja po odstawieniu lekow. Mi chodzilo o nieodwracalnych zmianach czynnosci watroby.

[ Dodano: 11-10-2005, 18:29 ]
Milk Thistle
Milk thistle for the treatment of liver disease: a systematic review and meta-analysis.

Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA.

Department of Medicine, University of California, San Francisco 94143, USA. [link widoczny dla zalogowanych Użytkowników]

PURPOSE: Milk thistle, an herbal compound, is the dietary supplement taken most frequently by patients with chronic liver disease. We performed a systematic review of the literature to determine the efficacy and safety of this herb for the treatment of liver disease. METHODS: We searched English and non-English reports through July 1999 using thirteen databases and reference lists, and contacting manufacturers and technical experts. Reviewers independently screened all reports to identify randomized placebo-controlled trials that evaluated milk thistle for the treatment of liver disease. Outcomes of primary interest included mortality, histological findings on liver biopsy specimens, serum aminotransferase and albumin levels, and prothrombin times. RESULTS: Fourteen trials met inclusion criteria. Four trials reported outcomes for mortality among 433 participants. The overall summary odds ratio for mortality in the milk thistle group compared with placebo was 0.8 (95% confidence interval [CI]: 0.5 to 1.5; P = 0.6). Three trials assessed histology on liver biopsy; study quality was inversely associated with the likelihood of histological benefit for milk thistle compared with placebo. There were no differences in serum alanine aminotransferase, aspartate aminotransferase, or albumin levels, or prothrombin times, among participants assigned to milk thistle compared with those assigned to placebo. The only statistically significant difference was a greater reduction in alanine aminotransferase levels among patients with chronic liver disease assigned to milk thistle (-9 IU/L, 95% CI: -18 to -1 IU/L; P = 0.05), but this reduction was of negligible clinical importance and no longer statistically significant after limiting analyses to studies of longer duration or of higher quality. The frequency of adverse effects was low and, in clinical trials, indistinguishable from placebo. CONCLUSION: Treatment with milk thistle appears to be safe and well tolerated. We found no reduction in mortality, in improvements in histology at liver biopsy, or in biochemical markers of liver function among patients with chronic liver disease. Data are too limited to exclude a substantial benefit or harm of milk thistle on mortality, and also to support recommending this herbal compound for the treatment of liver disease.







The use of silymarin in the treatment of liver diseases.

Saller R, Meier R, Brignoli R.

Abteilung Naturheilkunde, University Hospital Zurich, Switzerland.

The high prevalence of liver diseases such as chronic hepatitis and cirrhosis underscores the need for efficient and cost-effective treatments. The potential benefit of silymarin (extracted from the seeds of Silybum marianum or milk thistle) in the treatment of liver diseases remains a controversial issue. Therefore, the objective of this review is to assess the clinical efficacy and safety of silymarin by application of systematic approach. 525 references were found in the databases, of which 84 papers were retained for closer examination and 36 were deemed suitable for detailed analysis. Silymarin has metabolic and cell-regulating effects at concentrations found in clinical conditions, namely carrier-mediated regulation of cell membrane permeability, inhibition of the 5-lipoxygenase pathway, scavenging of reactive oxygen species (ROS) of the R-OH type and action on DNA-expression, for example, via suppression of nuclear factor (NF)-kappaB. Pooled data from case record studies involving 452 patients with Amanita phalloides poisoning show a highly significant difference in mortality in favour of silibinin [the main isomer contained in silymarin] (mortality 9.8% vs 18.3% with standard treatment; p < 0.01). The available trials in patients with toxic (e.g. solvents) or iatrogenic (e.g. antispychotic or tacrine) liver diseases, which are mostly outdated and underpowered, do not enable any valid conclusions to be drawn on the value of silymarin. The exception is an improved clinical tolerance of tacrine. In spite of some positive results in patients with acute viral hepatitis, no formally valid conclusion can be drawn regarding the value of silymarin in the treatment of these infections. Although there were no clinical end-points in the four trials considered in patients with alcoholic liver disease, histological findings were reported as improved in two out of two trials, improvement of prothrombin time was significant (two trials pooled) and liver transaminase levels were consistently lower in the silymarin-treated groups. Therefore, silymarin may be of use as an adjuvant in the therapy of alcoholic liver disease. Analysis was performed on five trials with a total of 602 patients with liver cirrhosis. The evidence shows that, compared with placebo, silymarin produces a nonsignificant reduction of total mortality by -4.2% [odds ratio (OR) 0.75 (0.5 - 1.1)]; but that, on the other hand, the use of silymarin leads to a significant reduction in liver-related mortality of-7% [OR]. An individual trial reported a reduction in the number of patients with encephalopathy of -8.7% (p = 0.06). In one study of patients with cirrhosis-related diabetes mellitus, the insulin requirement was reduced by -25% (p < 0.01). We conclude that available evidence suggests that silymarin may play a role in the therapy of (alcoholic) liver cirrhosis. Silymarin is has a good safety record and only rare case reports of gastrointestinal disturbances and allergic skin rashes have been published. This review does not aim to replace future prospective trials aiming to provide the 'final' evidence of the efficacy of silymarin.

Mam nadzieje ze rozumiecie angielski.